Gardasil
Generic name: human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
Treatment for: Human Papillomavirus Prophylaxis
Merck Submits Biologics License Application to FDA for Gardasil, the Company's Investigational Vaccine for Cervical Cancer
Cervical cancer is the second most common cause of cancer death in women worldwide, resulting in a half-million diagnoses and approximately 300,000 deaths each year. In the United States an estimated 10,000 new cases of cervical cancer will be diagnosed in 2005. In most people, HPV goes away on its own. In some, however, certain high-risk types of HPV, if unrecognized and untreated, can lead to cervical cancer. Also, approximately one million cases of genital warts occur each year in the United States.
Posted: December 2005
Related articles
- FDA: Gardasil Approved to Prevent Anal Cancer - December 22, 2010
- FDA Approves Gardasil for Use in Boys and Young Men - October 16, 2009
- FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers - September 15, 2008
- FDA Approves Gardasil for Prevention of Cervical Cancer other HPV-related Diseases - June 8, 2006
- FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of Gardasil - May 18, 2006
- Gardasil, Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration - February 7, 2006
- Biologics License Application for Gardasil, Merck's Investigational Cervical Cancer Vaccine, Is On Track - February 2, 2006
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
